BML Investment reports 11.9% stake in Aclaris
Aclaris Therapeutics, Inc. received an updated ownership report showing that BML Investment Partners, L.P. beneficially owns 14,250,000 shares of its common stock, representing 11.9% of the class as of 12/31/2025.
Rhea-AI Filing Summary
Aclaris Therapeutics, Inc. received an updated ownership report showing that BML Investment Partners, L.P. beneficially owns 14,250,000 shares of its common stock, representing 11.9% of the class as of 12/31/2025.
BML reports shared power to vote and dispose of all these shares, with no sole voting or dispositive power. The filing states the securities were not acquired or held for the purpose of changing or influencing control of Aclaris.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Aclaris Therapeutics (ACRS) Schedule 13G/A disclose about BML Investment's stake?
Does BML Investment seek to influence control of Aclaris Therapeutics according to the Schedule 13G/A?
Who ultimately controls BML Investment Partners’ Aclaris (ACRS) holdings according to the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.